Conduit Pharmaceuticals and Charles River Laboratories have announced a partnership to evaluate AZD1656, a glucokinase activator, in a preclinical model of systemic lupus erythematosus (SLE).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback